Business
Seres Therapeutics Appoints Lisa von Moltke, M.D., as Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc., (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke, M.D., FCP, as Executive Vice
About this update from Seres Therapeutics, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSeres Therapeutics, Inc., (Nasdaq: MCRB) today announced the appointment of Lisa von Moltke, M.D., FCP, as Executive Vice President and Chief Medical Officer. Dr. von Moltke joins Seres with an extensive career that includes senior leadership positions at Alkermes, Sanofi Genzyme and Millennium Pharmaceuticals/Takeda Oncology.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200406005187/en/Lisa von Moltke, M.D., FCP, Executive Vice President and Chief Medical Officer of Seres Therapeutics (Photo: Business Wire)\n\n“We are thrilled to welcome Dr. Lisa von Moltke as a key addition to our team. Lisa is joining Seres during an especially important period ahead of our anticipated SER-109 ECOSPOR III Phase 3 clinical readout in recurrent C. difficile infection,” said Eric Shaff, President and Chief Executive Officer of Seres. “Seres will benefit from Lisa’s extensive experience directing successful development programs, leading clinical teams, and interacting with regulatory agencies across multiple areas of medicine.”\n\n\n“I am excited to join Seres during such a pivotal time with the Company advancing promising development-stage therapeutic candidates for C. difficile infection, ulcerative colitis and cancer,” said Dr. von Moltke. “I look forward to working with the team to bring Seres’ innovative microbiome therapeutic approach, a new modality of medicine, forward to patients with serious diseases.”\n\n\nDr. von Moltke most recently served as Senior Vice President and Head of Clinical Development at Alkermes. Prior to that, she held positions as Vice President of Clinical and Exploratory Pharmacology at Sanofi Genzyme and Senior Director of Translational Medicine at Millennium Pharmaceuticals/Takeda Oncology. She has served as President of the American College of Clinical Pharmacology and as the Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. von Moltke earned her B.A. degree at Wellesley College and her M.D. from Michigan State University College of Human Medicine. She trained in internal medicine at New England Medical Center Hospital and started her career as a clinical pharmacology fellow at Tufts University School of Medicine and New England Medical Center Hospital.\n\n\nAbout Seres Therapeutics\n\n\nSeres Therapeu...